Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AXLANASDAQ:AYLANASDAQ:CRDFNASDAQ:FENCNASDAQ:GNFT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXLAAxcella Health$0.40-8.9%$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,700 shsAYLAAyala Pharmaceuticals$0.50+5.8%$0.48$0.36▼$7.31$7.46M1.9876,300 shs137,700 shsCRDFCardiff Oncology$4.35-0.5%$4.07$0.94▼$6.42$194.36M1.941.53 million shs606,899 shsFENCFennec Pharmaceuticals$9.34-2.4%$10.09$6.30▼$11.92$253.11M0.38111,209 shs143,207 shsGNFTGenfit$3.41-5.0%$3.62$2.89▼$4.75$169.92M1.0815,308 shs2,067 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXLAAxcella Health0.00%0.00%0.00%0.00%-96.17%AYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRDFCardiff Oncology-2.89%-22.93%-10.27%+189.40%+191.33%FENCFennec Pharmaceuticals-1.34%-11.63%-13.08%-4.40%+18.59%GNFTGenfit-0.29%-5.74%+0.88%+3.29%-9.22%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACRDFCardiff Oncology1.2592 of 5 stars3.52.00.00.03.40.00.0FENCFennec Pharmaceuticals2.3659 of 5 stars3.50.00.00.02.42.51.9GNFTGenfit0.7979 of 5 stars3.53.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXLAAxcella HealthN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/ACRDFCardiff Oncology3.00Buy$10.50141.38% UpsideFENCFennec Pharmaceuticals3.00Buy$17.3385.58% UpsideGNFTGenfit3.00Buy$11.00222.58% UpsideCurrent Analyst RatingsLatest AXLA, GNFT, AYLA, CRDF, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.003/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.003/1/2024CRDFCardiff OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21CRDFCardiff Oncology$490K396.65N/AN/A$1.56 per share2.79FENCFennec Pharmaceuticals$21.25M11.91N/AN/A($0.43) per share-21.72GNFTGenfit$41.31M4.11N/AN/A$1.48 per share2.30Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ACRDFCardiff Oncology-$41.44M-$0.93N/AN/AN/A-8,492.01%-50.13%-44.31%5/2/2024 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.34N/A-75.50%N/A-73.64%5/9/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)Latest AXLA, GNFT, AYLA, CRDF, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 million2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXLAAxcella HealthN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXLAAxcella HealthN/A0.800.80AYLAAyala PharmaceuticalsN/A2.282.28CRDFCardiff OncologyN/A7.417.41FENCFennec PharmaceuticalsN/A3.563.27GNFTGenfit0.922.942.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXLAAxcella Health65.07%AYLAAyala Pharmaceuticals22.10%CRDFCardiff Oncology16.29%FENCFennec Pharmaceuticals55.51%GNFTGenfit2.24%Insider OwnershipCompanyInsider OwnershipAXLAAxcella Health2.20%AYLAAyala Pharmaceuticals3.60%CRDFCardiff Oncology6.30%FENCFennec Pharmaceuticals11.25%GNFTGenfit4.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAXLAAxcella Health112.95 million2.88 millionOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableCRDFCardiff Oncology3144.68 million41.86 millionOptionableFENCFennec PharmaceuticalsN/A27.10 million24.06 millionOptionableGNFTGenfit15449.83 million47.74 millionNot OptionableAXLA, GNFT, AYLA, CRDF, and FENC HeadlinesSourceHeadlineGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documentsglobenewswire.com - April 15 at 4:10 PMGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-Fglobenewswire.com - April 5 at 2:00 PMGenfit's (GNFT) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - April 5 at 8:28 AMGENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - April 5 at 4:56 AMGENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 4 at 4:10 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Tradingmsn.com - April 3 at 12:51 PMGenfit S.A. (NASDAQ:GNFT) Short Interest Updatemarketbeat.com - April 2 at 10:00 AMEuropean Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Tradingmsn.com - March 27 at 1:06 PMGENFIT Announces Revenues and Cash Position as of December 31, 2023globenewswire.com - February 29 at 4:10 PMGENFIT S.A.thestreet.com - February 25 at 1:21 PMInventiva drops after adverse event in Phase 3 trial for NASH drugmsn.com - February 16 at 3:02 PMEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Tradingmsn.com - February 5 at 12:50 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Tradingmsn.com - January 29 at 1:31 PMGenfit Stock (NASDAQ:GNFT) Dividends: History, Yield and Datesbenzinga.com - December 21 at 3:56 PMGenfit SA ADR GNFTmorningstar.com - December 20 at 12:33 AMFDA grants priority review of Genfit-Ipsen liver disease drugmsn.com - December 7 at 7:56 AMIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCmarkets.businessinsider.com - December 7 at 2:56 AMGENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023benzinga.com - November 17 at 9:05 AMGENFIT Reports Third Quarter 2023 Financial Informationfinance.yahoo.com - November 9 at 6:14 PMOil Stocks Buoy European Equities Traded in the US as American Depositary Receipts Thursdaymsn.com - November 9 at 1:13 PMOil Stocks Burden European Equities Traded in the US as American Depositary Receipts Tuesdaymsn.com - November 7 at 12:41 PMGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technologyfinance.yahoo.com - September 26 at 8:22 PMGENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - September 26 at 3:22 PMGENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - September 22 at 9:33 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAxcella HealthNASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Ayala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Cardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.GenfitNASDAQ:GNFTGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.